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Highlights 
 α-Klotho is essential for maintaining cognitive function and brain health. 
 “Brain α-Klotho” is proposed as a distinct and vital pool of α-Klotho. 
 Brain α-Klotho has probable roles in neuroprotection and in promoting myelination. 
 The biggest gaps in our knowledge of α-Klotho function in the CNS are identified. 
 Experimental approaches to advance understanding of brain α-Klotho are suggested. 
 
ABSTRACT 
α-Klotho is well described as an anti-aging protein, with critical roles in kidney function as a 
transmembrane co-receptor for FGF23, and as a soluble factor in serum. α-Klotho is also 
expressed in the choroid plexus, where it is released into the cerebrospinal fluid. 
Nonetheless, α-Klotho is also expressed in the brain parenchyma. Accumulating evidence 
indicates that this pool of α-Klotho, which we define as brain α-Klotho, may play important 
roles as a neuroprotective factor and in promoting myelination, thereby supporting healthy 
brain aging. Here we summarize what is known about brain α-Klotho before focusing on the 
outstanding scientific questions related to its function. We believe there is a need for in 
vitro studies designed to distinguish between brain α-Klotho and other pools of α-Klotho, 
and for a greater understanding of the basic function of soluble α-Klotho. The mechanism by 
which the human KL-VS variant affects cognition also requires further elucidation. To help 
address these questions we suggest some experimental approaches that other laboratories 
might consider. In short, we hope to stimulate fresh ideas and encourage new research 
approaches that will allow the importance of α-Klotho for the aging brain to become clear. 
 
Abbreviated Title: Klotho signaling in the CNS  
Keywords: KLOTHO; CNS; cognition; signaling; aging. 
 
1. INTRODUCTION 
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α-Klotho is an antiaging protein named after Klotho, the Greek goddess who “spins the 
thread of life” (Kuro-o et al., 1997). Since its discovery interest in α-Klotho has grown 
steadily, with the idea that α-Klotho mutant animals can be instructive models for 
understanding aging in humans. This interest has intensified, with mutations in the human 
KL gene themselves linked to longevity (Arking et al., 2002).  α-Klotho loss-of-function mice 
display many features consistent with accelerated aging and have already produced useful 
mechanistic data explaining the adverse effect of kidney damage on life expectancy, and 
how the kidney maintains calcium and phosphate homeostasis. Most evidence so far 
suggests that these results are transferrable to humans. However, some key questions 
remain, and although α-Klotho is expressed in the brain and is vital for normal cognitive 
function, the role of this protein in neural tissues remains poorly understood.  
We begin this article by summarizing some of the central discoveries in the α-Klotho field. 
Where possible we have specified the type of α-Klotho protein that was assayed or used, 
although this important information is often unavailable. We then focus on the function of 
α-Klotho in the central nervous system (CNS). It is our contention that CNS α-Klotho plays a 
central role in maintaining brain health throughout life, and its loss with aging contributes to 
neurodegeneration and impaired cognition. As the major theme for this article, we suggest 
some key experimental questions that need to be addressed. Some are long unanswered, 
such as the reason for elevated α-Klotho expression in the choroid plexus, whereas others 
are inspired by more recent observations. We do not expect all suggested lines of research 
to be fruitful; our intention is simply to stimulate debate and help foster ideas. Nonetheless, 
we are convinced that α-Klotho plays a critical anti-aging role in the human CNS and as such, 
its study may be vital for understanding the effect of aging on the brain.  
2. DISCUSSION 
2.1 BACKGROUND 
2.1.1 Discovery of α-Klotho as an Anti-Aging Protein 
The initial discovery of the murine kl gene, which encodes α-Klotho, was somewhat 
serendipitous. Heterozygous mice carrying a non-expressing copy of a randomly inserted 
slc9a1 transgene were crossed and 1-in-4 of the resultant offspring displayed many features 
consistent with accelerated aging, such as genital atrophy, arteriosclerosis, ectopic 
calcification, osteoporosis, skin atrophy, infertility, and emphysema. Most strikingly, the 
animals have an average life span of just 61 days (Kuro-o et al., 1997). Subsequent 
investigations revealed that the inserted transgene had caused an 8kb deletion 6kb 
upstream of the first exon of kl, resulting in an almost complete loss of α-Klotho mRNA. 
Since these animals retain some α-Klotho expression, kl/kl homozygotes are considered 
hypomorphs rather than knockouts.  
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The multi-organ kl/kl hypomorph phenotype was surprising, since the authors also reported 
a very restricted pattern of gene expression, with transcripts encoding α-Klotho most 
abundant in the kidney, brain, pituitary gland and reproductive organs of wild-type animals, 
but undetectable in most other tissues (Kuro-o et al., 1997). Nonetheless there can be no 
doubt about the profound effects of losing α-Klotho expression, as the cardinal features of 
the kl/kl hypomorph have been replicated independently in of other loss-of-function animal 
models. These include two global knockouts (Olauson et al., 2012; Tsujikawa et al., 2003) 
and two strains of mice with kl mutations identified as part of an ENU screen for genes 
involved in ectopic calcification (Esapa et al., 2015). The restricted tissue expression pattern 
has also been confirmed and appears to be conserved amongst mammals (Lim et al., 2015). 
Strengthening the link between α-Klotho and aging further, mice overexpressing α-Klotho 
have been reported to live 30% longer than their wild-type littermates (Kurosu et al., 2005).  
Importantly, α-Klotho is also linked to aging in humans. The so-called KL-VS variant, which 
contains two co-inherited amino acid substitutions, F352V and C370S, has been reported to 
decrease life expectancy in homozygotes. Curiously, individuals heterozygous for this allele 
(i.e., KL-VS carriers) have an increased life span (Arking et al., 2002) and decreased 
cardiovascular disease risk (Arking et al., 2005). The reason for this contradiction is unknown 
(see Section 3.8). Beyond KL-VS status, total levels of α-Klotho in sera and cerebrospinal 
fluid (CSF) from humans and mice are reported to decrease with age (Semba et al., 2014; 
Yamazaki et al., 2010), whilst the expression of this protein in brain white matter is reduced 
in mice and monkeys (Duce et al., 2008). Taken together, these observations indicate that 
loss of α-Klotho is central to aging in mammals. 
2.1.2 Membrane-bound, shed and secreted α-Klotho  
α-Klotho protein exists in five different forms – a transmembrane protein, three shed forms, 
and a secreted protein (Figure 1). The transmembrane and shed forms are the product of 
the same mRNA transcript, which initially produces a ~130kDa single-pass transmembrane 
protein, referred to herein as m-KL. m-KL consists of short transmembrane and intracellular 
sequences at the c-terminus, as well as a large extracellular section containing two KL 
domains, KL1 and KL2. Each of these KL domains possesses glucosidase activity and is able to 
cleave sialic acid from the carbohydrates of glycoproteins (i.e. desialylation). To date, only a 
handful of proteins have been reported as targets of α-Klotho glucosidase activity, with the 
best described being the calcium channels TRPV5 and TRPV6 (Chang et al., 2005; Lu et al., 
2008). Desialylation of these calcium channels allows their binding to the extracellular 
glycan-binding protein galectin-1, leading to their clustering and retention on the plasma 
membrane, with a resultant increase calcium channel activity. 
The shed forms of α-Klotho are released from the cell surface by proteolytic cleavage of m-
KL by the metalloproteinases ADAM10 and ADAM17 (Chen et al., 2007). Two cleavage sites 
have been identified: the first immediately adjacent to the plasma membrane; the second 
5 
 
between the KL1 and KL2 domains. Cleavage at the juxtamembrane site releases a protein 
containing both KL1 and KL2 domains (p-KL), whereas cleavage at the second releases a 
protein containing just the KL1 domain (p-KL1). Cleavage at both sites leads to the shedding 
of p-KL1 and a second protein containing KL2 (p-KL2) (Chen et al., 2014a). By contrast, 
secreted α-Klotho (s-KL) is produced by an alternative splicing event that introduces a short 
and unique sequence immediately after KL1, producing a protein that is almost identical to 
p-KL1, but with a distinct C-terminus (Matsumura et al., 1998). It is not known if this small C-
terminal sequence confers any functional differences between s-KL and p-KL1. As the name 
would suggest, it is assumed that s-KL is secreted, and likely resides only within extracellular 
fluids and the lumen of intracellular vesicles.  
A detailed review of our current understanding of the basic biological function of α-Klotho is 
beyond the scope of this article. Nonetheless, it is reasonable to summarize m-KL as a 
component of cell surface receptor complexes, while secreted and shed forms act as 
humoral or endocrine factors. However, it is worth observing that very few publications 
make a distinction between shed and soluble forms, instead referring to “soluble α-Klotho”. 
It is of course highly unlikely that the different types of soluble α-Klotho will have exactly 
the same function. Much of this vagueness has been due to the absence of selective 
antibodies, but we expect technical advances will allow these key details to be filled in in 
future.  
2.1.3 α-Klotho and the CNS  
Expression in the choroid plexus. The epithelial cells of the four choroid plexuses of the brain 
(collectively, “the choroid plexus”) were identified as sites of abundant α-Klotho expression 
in the original description of this protein (Kuro-o et al., 1997), an observation that has since 
been replicated by others. At present we do not know why α-Klotho expression is high in the 
choroid plexus, but based on what is known about these structures, some reasonable 
assumptions can be made.  
The choroid plexus has three roles: i) a barrier between blood and cerebrospinal fluid (CSF); 
ii) the major source of CSF production; and iii) a source of secreted soluble factors for the 
CSF (Damkier et al., 2013). Since soluble α-Klotho protein is detectable in CSF, it is 
reasonable to assume this protein has been produced by the choroid plexus. As such, α-
Klotho expression in the choroid plexus is likely to be analogous to α-Klotho expression in 
the kidney (see section 2.4); in the same way the kidney supplies soluble α-Klotho to serum, 
the choroid produces this protein for the CSF. This comparison is perhaps unsurprising, as 
the kidney and choroid plexus are so similar at the gene expression level that the choroid 
plexus has actually been referred to as “the kidney of the brain” (Sathyanesan et al., 2012). 
Expression in the rest of the brain. α-Klotho mRNA is also detectible, albeit at lower levels, in 
several other brain regions, including cortex, hippocampus, cerebellum, striatum, substantia 
nigra, olfactory bulb and medulla (Brobey et al., 2015; Clinton et al., 2013; German et al., 
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2012; Li et al., 2004). Lack of suitable antibodies have hampered studies of α-Klotho 
expression at the protein level, but are nonetheless consistent with expression in multiple 
brain regions, and in both neurons and oligodendrocytes (Brobey et al., 2015; Clinton et al., 
2013; Degaspari et al., 2015; German et al., 2012; Li et al., 2004). Since there is no evidence 
α-Klotho can cross the blood-brain barrier and there is very little fluid exchange between 
the CSF and the interstitial fluid of the brain parenchyma, we can be reasonably confident 
that α-Klotho protein detectable in the brain (‘brain α-Klotho’) has been expressed locally. 
As such we consider brain α-Klotho a distinct pool of α-Klotho, separate from serum α-
Klotho and α-Klotho produced by the choroid plexus (‘CSF α-Klotho’). The role of brain α-
Klotho is the major focus this review. 
Fascinatingly, the relative expression of s-KL mRNA compared to m-KL mRNA is higher in the 
brain than other organs, and far more so in humans than mice (Massó et al., 2015; 
Matsumura et al., 1998), suggesting that soluble forms of α-Klotho may be most important 
in this organ. A role for m-KL cannot be excluded entirely though. As we describe in the next 
section, m-KL functions as a co-receptor for FGF23 in the kidney, and it is interesting to note 
that a related protein, β-Klotho, acts as a transmembrane co-receptor for FGF21 in the 
suprachiasmatic nucleus (Bookout et al., 2013). However, m-KL is highly selective for FGF23, 
and there is little evidence that FGF23 is active in the brain, beyond the intriguing study of 
Hensel and colleagues (Hensel et al., 2016). In this paper, mouse hippocampal neurons were 
reported to display altered neuronal morphology and changes in cell signaling in response to 
recombinant FGF23. Curiously, the observed effects appear to be modulated by soluble α-
Klotho, indicating that the lack of m-KL in the brain does not necessarily preclude a role for 
brain α-Klotho in FGF23 signaling (Hensel et al., 2016). But in any case, the combined data 
point towards a primary requirement for brain α-Klotho as s-KL, and suggest that this role 
may be especially important more developed brains of humans. 
Requirements of α-Klotho for brain function. The majority of in vivo studies have not 
distinguished between pools of α-Klotho, but the evidence suggests that this protein is 
required at many levels for normal brain health. The initial report of kl/kl hypomorphs 
described hypokinesis at 5-weeks of age caused by degeneration of Purkinje cells in the 
cerebellum (Kuro-o et al., 1997). Subsequent investigations in the hippocampi of these 
animals have reported loss of synapses, perturbations in axonal transport, alterations in 
neurofilaments and accumulation of lysosomes (Li et al., 2004; Shiozaki et al., 2008; Uchida 
et al., 2001). Suggesting a relevance of α-Klotho to Parkinson’s disease, midbrain 
dopaminergic neurons also show evidence of neurodegeneration (Kosakai et al., 2011), 
while anterior horn cells present degenerative features similar to those found in humans 
with amyotrophic lateral sclerosis (Anamizu et al., 2005). Unsurprisingly, by seven-weeks of 
age the mice display severe cognitive impairments, associated with cholinergic dysfunction 
(Park et al., 2013), oxidative damage and apoptotic stress. The CNS phenotype of kl/kl mice, 
as well as the action of certain treatments reported to ameliorate the degeneration, such as 
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α-tocopherol (Nagai et al., 2003) and melatonin (Shin et al., 2015), are shown in Figure 2. 
Supporting these data, mice over-expressing α-Klotho show improved cognition and appear 
resistant to neurodegeneration caused by overexpression of the Alzheimer’s disease protein 
hAPP (Dubal et al., 2014; Dubal et al., 2015), and also by treatment with MPTP, a well-
established Parkinson’s disease model (Brobey et al, 2015).  
As we explain in Section 2.4, much of the brain phenotype of kl/kl mice appears to be 
secondary to kidney damage. Nonetheless there is good evidence of a specific role for brain 
α-Klotho in maintaining normal brain function. In particular, lower α-Klotho mRNA levels 
have been reported in hippocampi taken from post-mortem human epilepsy patients 
(Teocchi et al., 2013), and in the white matter of aged rhesus monkeys (Duce et al., 2008). 
Interestingly, CSF α-Klotho is also reported to decrease with age and in patients with 
Alzheimer’s disease and relapsing-remitting multiple sclerosis (Aleagha et al., 2015; Semba 
et al., 2014) 
A requirement for α-Klotho in human cognition has largely been corroborated through 
studies of the KL-VS variant. These studies suggest a discordance between the phenotypes 
of KL-VS hetero- and homozygotes that mirror observations for longevity. In the first such 
study, Deary and co-workers reported decreased IQ in individuals homozygous for KL-VS, 
with heterozygotes unchanged compared to controls (Deary et al., 2005). By contrast, two 
subsequent publications reported improved cognition in heterozygotes (Dubal et al., 2014; 
Yokoyama et al., 2015). Consistent with a link between α-Klotho and neurodegeneration, KL-
VS carriers were also found to display increased brain volumes (Yokoyama et al., 2015). Lack 
of numbers prevented KL-VS homozygotes from being studied as thoroughly, but it is 
fascinating to note that a strong trend towards decreased brain volume was observed in the 
few individuals examined (Yokoyama et al., 2015). Thus, mirroring the effect of KL-VS on 
longevity, higher brain function appears enhanced in KL-VS carriers, but weakened in 
homozygous individuals.  
Effects of α-Klotho on neural cells in vitro. Supporting brain α-Klotho acting as a soluble 
factor are the growing number of papers reporting biological effects of recombinant p-KL or 
p-KL1 protein on neural cell lines. Indeed, the evidence that soluble α-Klotho is 
neuroprotective appears overwhelming. These include resistance to oxidative and 
endoplasmic reticulum stresses, and protection from cytotoxicity elicited by the Alzheimer’s 
disease protein Aβ and glutamate excitotoxicity (Cheng et al., 2015; Zeldich et al., 2014). A 
number of cell signaling pathways have been reported as modulated by α-Klotho and 
suggested to underlie these observations, including the PI3K/Akt, ASK1/p38 MAPK and PERK 
pathways (Banerjee et al., 2013; Brobey et al., 2015; Zeldich et al., 2014). Experiments by 
Xin and colleagues, showed α-Klotho participation in oxidative stress resistance in cortical 
neurons and cerebellar granule cells. Stimulation of α-Klotho expression by DNA 
demethylation, decreased apoptotic cell death under H2O2 treatment (Xin et al., 2015). 
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Conversely, the protective effect was lost with α-Klotho inhibition with shRNA. The effects 
α-Klotho on cell signaling pathways in neural cells are depicted in Figure 3.   
Recombinant p-KL also affects the behavior of other neural cell types. In particular, work 
from Carmela Abraham’s laboratory has identified oligodendrocytes as a likely target of 
soluble α-Klotho. These studies have reported that recombinant p-KL promotes the 
differentiation and myelination of a human oligodendrocytic hybrid cell line (Chen et al., 
2015a), and the maturation of rat oligodendrocytes in vitro (Chen et al., 2013a), via the co-
ordinate regulation of several key signaling pathways including Wnt, NFκB, p53, Akt and 
ERK. Since kl/kl hypomorphic mice display decreased myelination (Chen et al., 2013b) and 
mice over-expressing α-Klotho display enhanced remyelination after cuprizone-induced 
demyelination (Zeldich et al., 2015), the control of myelination seems a likely physiological 
role for brain α-Klotho. 
2.1.4 α-Klotho and the Kidney  
Although this article focuses on the CNS, α-Klotho expressed in the kidney needs some 
mention, since, as alluded to above, this pool of α-Klotho has a clear influence on the CNS. 
In the kidney the primary function of α-Klotho is in its m-KL form, acting as a co-receptor for 
FGF23. This role is highly conserved throughout evolution, certainly as far as zebrafish 
(Mangos et al., 2012) and perhaps as far as nematodes (Château et al., 2010). Through 
mediation of FGF23 signaling, m-KL forms part of a multi-organ regulatory mechanism that 
controls the levels of circulating calcium, phosphate and vitamin D (Erben and Andrukhova, 
2016). Importantly, much of the kl/kl phenotype, including neuropathological and cognitive 
defects, can be attributed to loss of renal FGF23 signaling. Most strikingly, an animal with 
kidney-specific deletion α-Klotho (“Six2-kl”) has been reported to phenocopy kl/kl mice 
(Lindberg et al., 2014). Although the cognitive function and neuropathology of Six2-kl mice 
is unreported, it is not unreasonable to assume an impairment since like kl/kl mice these 
animals have elevated vitamin D levels (Lindberg et al., 2014). Restoring vitamin D levels can 
rescues much of the kl/kl phenotype, including loss of dopaminergic neurons (Carpinelli et 
al., 2011; Kosakai et al., 2011; Leibrock et al., 2016).  
Taken together, these observations indicate that by regulating vitamin D homeostasis (and 
perhaps also calcium and phosphate) renal m-KL is essential for health throughout the body, 
including the brain. However, the state of the kidney may influence brain health in multiple 
ways. Cognitive impairment is common in patients with chronic kidney disease (CKD), and 
within the general population decreased kidney function is a risk factor for future cognitive 
decline (Hermann et al., 2014). The mechanism by which CKD causes cognitive decline 
appears distinct to the neurological defects seen in kl/kl mice since CKD is an established 
cause of decreased vitamin D levels. However, the kidneys are also the source of the 
majority (perhaps all) of the soluble α-Klotho in serum (Lindberg et al., 2014), and increased 
levels of serum α-Klotho are correlated with reduced risk of cognitive decline (Shardell et al., 
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2016). Intriguingly, a number of publications report decreased serum α-Klotho in CKD, while 
serum α-Klotho levels are also reduced in rodent kidney damage models. Thus, brain health 
may be subject to control via the function of renal m-KL, and also through soluble forms of 
α-Klotho produced in the same organ. 
Data from our own study indicate another layer of complexity in the linkage between the 
kidney, the CNS and α-Klotho. Using 5/6-nephrectomized rats to study cognitive 
performance following kidney damage, we found that approximately half the 
nephrectomized animals developed clear memory impairment in the inhibitory avoidance 
test. Intriguingly, in comparison to both sham surgery controls and nephrectomized animals 
that did not develop memory impairment, these animals displayed a marked decrease in 
levels of α-Klotho in the pre-frontal cortex. Thus, in addition to causing cognitive 
impairment and decreasing serum α-Klotho, kidney damage also reduces α-Klotho in the 
brains of animals, a decrease that is associated with cognitive impairment (Degaspari et al., 
2015).  
2.2 OUTSTANDING QUESTIONS 
2.2.1 What does brain α-Klotho do? 
Current data point towards brain α-Klotho functioning as a soluble factor that alters neural 
cell behavior by modulating intracellular signal transduction cascades. However, this 
highlights one of the more conspicuous gaps in our knowledge: the missing identity of the 
membrane receptor(s) through which soluble α-Klotho signals. Both m-KL and soluble forms 
have been reported to inhibit canonical Wnt signaling by interfering with the interactions 
between Wnt ligands and their receptors (Liu et al., 2007; Sun et al., 2015). Suggesting that 
this is relevant to the brain, p-KL represses Wnt signaling in oligodendrocyte cell models 
(Chen et al., 2013a; Chen et al., 2013b), and the suppression of this pathway has been 
shown by others to promote oligodendrocyte differentiation (Guo et al., 2015). However, 
Wnt inhibition is highly unlikely to be the only mechanism by which brain α-Klotho signals. 
Both in oligodendrocyte and neurons, recombinant α-Klotho stimulates numerous other 
signaling pathways. Moreover, the rapid activation of these cascades is largely inconsistent 
with them being downstream of canonical Wnt inhibition. As such, one must assume that 
alternative protein targets for brain α-Klotho are present in the brain. 
One intriguing possibility given the established nature of the brain as an electrically active 
organ, is that via its glucosidase activity α-Klotho may regulate the function of glycosylated 
ion channels and transporters. In principle, modulation of electrochemical gradients on 
neural cell membranes could affect the activity of many cell signaling cascades. At present 
we know very little about which glycoproteins are targeted by α-Klotho (in the brain or 
elsewhere), although we note that the renal α-Klotho targets TRPV5 and TRPV6 are 
expressed in brain (Kunert-Keil et al., 2006). Furthermore, galectin-1, which binds desialated 
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TRPV5 and TRPV6 and mediates their clustering, is reported to be neuroprotective (Wang et 
al., 2015). With this in mind it is also worth highlighting the growing links between α-Klotho 
and Na,K-ATPases, a family of sodium/potassium pump present on plasma membranes. This 
connection was first described in a report that m-KL directly interacts with the Na, K-ATPase 
α1 subunit in kidney, parathyroid and choroid plexus, and facilitates the recruitment of the 
Na, K-ATPase α1 subunit to the plasma membrane in response to Ca+2 oscillations (Imura et 
al., 2007). As extracellular Ca2+ levels decrease, α-Klotho expression is upregulated, 
increasing α1 subunit transport to the membrane and Na pump activity. This response is lost 
in kl/kl mice (Imura et al., 2007).  Intriguingly, subsequent data suggest that p-KL also 
enhances Na, K-ATPase activity, and that this effect is entirely dependent on glucosidase 
activity (Sopjani et al., 2011). As such, if we assume brain α-Klotho acts primarily as a 
secreted factor, Na,K-ATPases could well be key targets of this protein. However, this story 
does not end here. In addition to maintaining plasma membrane electrochemical gradients, 
Na,K-ATPases are now established as an unusual class of transmembrane receptors that 
mediate signaling elicited by ouabain and related compounds (Kawamoto et al., 2012; Lima 
et al., 2013). Through interactions with Src tyrosine kinases and IP3-receptors, Na,K-ATPases 
mediate the activation of Src tyrosine kinase- and intracellular Ca+2-dependent signaling 
cascades, respectively (Aperia et al., 2016; Madan et al., 2016). Although classically 
described as a compound that affects the heart, ouabain is emerging as a potent 
neuroprotective agent (Kinoshita et al., 2016), and the Na+/K+-ATPase α3 isoform plays an 
important role in the control of spatial learning and memory (Holm et al., 2016). Taken 
together, these observations make a role for brain α-Klotho as a regulator of Na,K-ATPase-
dependent cell signaling an exciting suggestion. 
In any case, the functions of brain α-Klotho are a long way from being fully resolved. At 
present, we would argue that the lack of knowledge regarding the physiological targets of 
soluble forms of α-Klotho is a major limitation. Thus, we would argue that there is a need 
for unbiased glycomics approaches to identify substrates of α-Klotho glucosidase activity in 
neural tissues. One might imagine a study where isolated membrane fractions from brain 
are treated with and without recombinant α-Klotho, and glycoproteins affinity purified with 
carbohydrate-binding proteins, prior to identification by mass spectrometry. In principle, 
the desialylation of α-Klotho substrates will alter their affinity for the relevant carbohydrate-
binding protein; for example, if galectin-1 is used, the amount of the α-Klotho substrate 
TRPV5 purified would increase significantly after treatment with recombinant α-Klotho. In 
this way, we would expect new and perhaps unexpected targets of brain α-Klotho to 
announce themselves, hopefully leading to more solid answers for the function of this 
protein in future. 
2.2.2 Is brain α-Klotho involved in cognition? 
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The evidence from mice and from humans is clear; α-Klotho is required for normal higher 
brain function, with cognitive performance correlated with levels of soluble α-Klotho in 
serum. But can we say the same specifically for brain α-Klotho? At present, no. All studies 
performed to date have been unable to distinguish between the requirement for brain and 
other pools of α-Klotho. Indeed, brain α-Klotho may affect the behavior of neurons and 
oligodendrocytes in vitro, but when it comes to tests of learning and memory performed in 
vivo, there is perversely more evidence of a requirement for α-Klotho produced in the 
kidney.  
However, we are now in a position where direct testing of the requirement for brain α-
Klotho in higher brain function is possible, using Cre-mediated brain-specific knockout of α-
Klotho (or alternatively, brain region-specific knockout). In particular, the klothoflox/flox mice 
described by Olauson and colleagues that contain Flox sites either side of kl exon 2 
(Lindberg et al., 2014; Olauson et al., 2012), could be crossed with a suitable Cre strain. For 
example, crossing with Thy1-cre mice would ablate α-Klotho expression in the hippocampus 
and forebrain. Such an animal would be expected to express α-Klotho normally outside the 
brain and thus avoid the debilitating consequences of decreased kidney α-Klotho. Examining 
this animal in conventional rodent behavioral tests (e.g. inhibitory avoidance, Morris water 
maze, elevated plus maze etc.) in comparison to appropriate littermate controls, should 
demonstrate convincingly whether α-Klotho expressed in brain is necessary or dispensable 
for normal cognition. 
2.2.3 Is brain α-Klotho neuroprotective?  
α-Klotho is required for maintaining the health of a variety of tissues, and has been shown in 
in vivo studies of organs other than the brain to regulate processes that are known to affect 
neuroprotection, such as inflammation (Liu et al., 2011; Maekawa et al., 2009; Zeng et al., 
2016) and metabolic sensing pathways (Château et al., 2010; Kurosu et al., 2005). 
Nonetheless, the most significant data suggesting a direct neuroprotective action of α-
Klotho come from studies of neuronal cell death in vitro: we are unaware of any direct 
studies in vivo. To address this question we would suggest a brain-specific knockout strategy 
akin to that described in the previous section. However, rodents are relatively resistant to 
neurodegeneration – for example, several mutations that cause Parkinson’s disease in man 
fail to elicit any overt phenotype in mice – and thus any loss of neurons may be below 
detectable thresholds. To overcome this potential problem, we would recommend also 
investigating the effects of brain-specific α-Klotho knockout in an established and reliable 
neurodegenerative disease background, such as the 3xTg Alzheimer’s disease mouse model 
(Oddo et al., 2003). Here, with robust levels of neurodegeneration guaranteed, the 
consequence of losing a potential neuroprotective factor might be more easily observed. 
This loss-of-function approach would, of course be strengthened if the effect of increasing 
brain α-Klotho were studied in parallel. At present, we do not have means to do this 
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genetically, but levels of soluble α-Klotho in the brain could be increased through 
stereotactic injection of recombinant protein or viral transduction of DNA encoding α-
Klotho. In principle, combined loss- and gain-of-function data would make a powerful case 
for the status of brain α-Klotho as neuroprotective.  
2.2.4 Does loss of serum α-Klotho cause cognitive decline?   
Interestingly, impaired cognition is a consequence of both kidney damage or CKD, and 
decreased α-Klotho production in the kidney. However, the mechanisms appear distinct, 
since loss of renal α-Klotho exerts its effects, at least in part, through hypervitaminosis D, 
whereas CKD causes decreased vitamin D levels. Nonetheless, both situations lead to 
decreased levels of soluble α-Klotho in serum. Since serum α-Klotho is itself linked to 
cognitive decline, these observations lead to a fairly natural question: do serum α-Klotho 
levels affect higher brain function? 
The obvious approach to answering this question would be to generate mice that 
specifically lack serum α-Klotho. However, this will not be easy. In the mouse, the vast 
majority of serum α-Klotho (perhaps all) is produced by proteolysis of renal m-KL. Any loss-
of-function strategy will therefore have to reduce shedding without compromising m-KL 
expression and function. This is not impossible though. Chen and colleagues have described 
a metalloproteinase resistance m-KL mutant with severely reduced shedding (~94%), but 
only a minor weakening in FGF23 signaling (Chen et al., 2014a). In principle therefore, a 
knock-in mouse containing a metalloproteinase resistant m-KL could be generated. 
However, to address the importance of serum α-Klotho we would suggest the first step 
would be to determine whether loss of serum α-Klotho caused by kidney damage is 
necessary for the effects of kidney damage on cognition. Specifically, whether the 
administration of recombinant α-Klotho protein will rescue learning impairments in the 
nephrectomy model. Importantly, this strategy appears feasible, since intraperitoneal 
injections of α-Klotho have been used to ameliorate symptoms and extend life expectancy 
by 17.4% in kl/kl mice (Chen et al., 2013a). 
2.2.5 How does kidney damage cause loss of α-Klotho in the brain? Is it via decreased 
serum α-Klotho? 
Our observation of decreased α-Klotho protein in the pre-frontal cortex of nephrectomized 
mice (Degaspari et al., 2015) indicates that kidney damage can affect α-Klotho expression in 
other organs, and adds to the mounting evidence that renal impairment impacts on 
cognition. However, our work also raises the questions of how kidney damage is able to 
elicit decreased brain α-Klotho, and whether this is dependent upon loss of serum α-Klotho.  
The involvement of serum α-Klotho can be answered using the same approaches described 
for investigating the role of this pool of α-Klotho in cognition; determining whether 
decreased brain α-Klotho following nephrectomy can be rescued with intraperitoneal 
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injections of recombinant α-Klotho. Nonetheless, when attempting to uncover the 
mechanism linking two biological events it is always sensible to look from both ends. Thus, 
an additional consideration is how brain α-Klotho expression levels are regulated. Since 
brain α-Klotho was measured by ELISA in our study, we are unable to say if decreased levels 
are due to lowered expression or increased turnover. We are unaware of any studies 
investigating the control of α-Klotho at the level of its translation or protein stability, 
although α-Klotho has been reported as being ubiquitinated (Wagner et al., 2012), 
suggesting protein stability could perhaps be under dynamic control. Some studies of α-
Klotho gene expression have been reported, indicating that the kl promoter can be 
activated by testosterone and the androgen receptor (Hsu et al., 2014), and by the 
transcription factor Egr-1 (Choi et al., 2010). Perhaps most intriguingly however, α-Klotho 
transcription is strongly repressed by promoter methylation (Azuma et al., 2012; King et al., 
2012; Sun et al., 2012). This phenomenon has been suggested to underlie the tightly 
controlled tissue-specific pattern of α-Klotho expression (Azuma et al., 2012) and is reported 
to increase with age (King et al., 2012). Interestingly, increased KL promoter methylation has 
also been described in a number of cancers, including cervical carcinoma, colorectal, breast 
and gastric cancers (Lee et al., 2010; Pan et al., 2011; Rubinek et al., 2012; Wang et al., 
2011). Fascinatingly, promoter methylation may be important to our observations. In 
studies combining in vivo experiments in the murine kidney and in vitro work in human 
tubular cells, Sun and co-workers found that elevated levels of uremic toxins – a side-effect 
of kidney impairment – lead to increased expression of DNA methyltransferase (Sun et al., 
2012). This, in turn, was found to cause kl promoter hypermethylation and down-regulation 
of α-Klotho transcription. Since uremic toxins are believed to act via inflammatory pathways 
and we see evidence of neuroinflammation in our system, it is quite possible that elevated 
promoter methylation underlies the decreased brain α-Klotho seen in nephrectomized rats. 
Supporting this idea further, kl promoter methylation can be modulated in the brain, since 
an age-dependent increase that correlates with decreased protein expression has been 
reported in the white matter of rhesus monkeys (King et al., 2012). Altered promoter 
methylation in the brains of our animals is clearly a hypothesis that can be tested relatively 
easily. 
Finally, a very simple alternative mechanism for the control of brain α-Klotho by kidney 
damage should be acknowledged. As we have mentioned, there is no evidence that serum 
α-Klotho is able to cross the blood-brain barrier, but we are unaware of any studies testing 
this directly. If serum α-Klotho can cross the blood-brain barrier, it is not inconceivable that 
much or all of the pre-frontal cortex α-Klotho protein measured by ELISAs has in fact come 
from the kidney. Although this mechanism is perhaps unlikely, it is undeniable that this 
would be sufficient to explain the observed decrease in α-Klotho following nephrectomy. 
2.2.6 Could increasing α-Klotho treat neurodegenerative disease? 
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As we have outlined, α-Klotho expression is linked by numerous lines of evidence to brain 
health, including protection from neurodegeneration in a mouse Alzheimer’s disease model 
(Dubal et al., 2015). The relative contributions of the different pools of α-Klotho remain to 
be determined, but the data suggest that therapeutic strategies to increase global α-Klotho 
levels may have potential to halt cognitive decline and increase neuronal survival (Abraham 
et al., 2012).  
As illustrated in Figure 4, a growing list of factors have been reported to influence α-Klotho 
expression, both positively and negatively. Interestingly, these include soluble Amyloid 
precursor protein, which upregulates  α-Klotho expression (Li et al., 2010), indicating that in 
pathological amyloidogenic conditions such as Alzheimer’s Disease, proper α-Klotho 
expression might be impaired. Consistently, α-Klotho is decreased in the serum and brain of 
AD animal models (Kuang et al., 2014; Massó et al., 2015) and also in the CSF of humans 
(Semba et al., 2014). 
More relevant for potential treatments to elevate α-Klotho expression is the work of Kuang 
and colleagues, who studied the effect of the neuroprotective compound ligustilide in 
SAMP8 mice, an accelerated aging model that develop a number of Alzheimer’s disease 
features, such as Aβ accumulation and tau phosphorylation (Kuang et al., 2014). Strikingly, 
alongside improvements in numerous measures of brain health, this report found ligustilide 
to elevate levels of α-Klotho in serum and in the choroid plexus (Kuang et al., 2014). 
There are two limitations to the Kuang study. Firstly, the authors do not show whether α-
Klotho actually contributes to the neuroprotective mechanism of ligustilide. Presumably the 
expression levels of other genes may be changed, some of which may also be involved in the 
neuroprotection. Secondly, SAMP8 mice have an aging, rather than a pure 
neurodegenerative phenotype – the extent to which these animals represent human 
Alzheimer’s disease is open to debate. Thus, to test the effect of ligustilide further, we 
would suggest studying the effects of compounds reported to elevate α-Klotho expression in 
a more recognized Alzheimer’s disease model. In addition, to provide some evidence that α-
Klotho is involved in neuroprotection, we would suggest the need for parallel studies 
examining the effect of unrelated α-Klotho elevating compounds. Although such 
experiments do not prove a requirement for α-Klotho, they would certainly strengthen the 
case.  
2.2.7 What is the target of Choroid Plexus / CSF α-Klotho? 
As already observed, little is known about the role of choroid plexus α-Klotho, although a 
role as a transmembrane receptor can probably be discounted, since in vitro studies have 
shown that the only FGF receptor transmembrane α-Klotho cannot form a co-receptor 
complex with is FGFR2, and FGFR2 is the only FGF receptor isoform expressed in murine 
choroid plexus (Reid and Ferretti, 2003). Thus, it is very unlikely that α-Klotho is able to 
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mediate FGF23 signaling in choroid plexus epithelial cells. As such, the assumed reason for 
high α-Klotho expression in the choroid plexus is for it to be released into the CSF as a 
neuroendocrine factor. 
This, though, leads to another key question: what is the target of CSF α-Klotho? Since there 
is little exchange between the interstitial fluid of the brain parenchyma and the CSF, the 
most likely targets are within the brain stem and spinal cord. In agreement with this, certain 
data point towards the medulla oblongata, a neuronal mass involved in regulating blood 
pressure. It is well established that altering the chemical composition of the CSF can affect 
the medulla oblongata, and a small number of publications suggest that CSF α-Klotho may 
be one such factor. Specifically, intracerebroventricular injection of α-Klotho siRNA has been 
reported to increase blood pressure in both Sprague Dawley (Wang and Sun, 2010) and WKY 
rats (Chen et al., 2015b). This same treatment appears to impair the baroreflex – the rapid 
negative feedback mechanism by which the body reacts to sudden changes in blood 
pressure by altering the heart rate (Chen et al., 2015b). Conversely, in animals with impaired 
baroreflexes, increasing CSF α-Klotho by intracerebroventricular injection of recombinant 
protein elicits an improved response (Chen et al., 2015b; Chen et al., 2014b). Interestingly, 
siRNA-mediated knockdown of α-Klotho was confirmed in choroid plexus samples by PCR 
and Western blotting (Wang and Sun, 2010), but only by Western blotting in the medulla 
oblongata (Chen et al., 2015b) . This last observation is fascinating since it is consistent with 
α-Klotho being able to modulate the medulla oblongata, but does not demonstrate where 
this protein came from. In principle, the protein is likely to be soluble α-Klotho produced in 
the choroid plexus, but the possibility that it was made in the medulla oblongata itself 
cannot be excluded. There is therefore a clear need to demonstrate α-Klotho expression in 
the medulla oblongata at the mRNA level. But in any case, taking these papers together, it is 
clear that α-Klotho is central to the maintenance of normal blood pressure. Furthermore, it 
is likely that this involves endocrine modulation of the medulla oblongata by α-Klotho from 
the choroid plexus. 
Intriguingly, this hypothesis can perhaps be extended further, since rats subjected to chronic 
unpredictable stress show decreased α-Klotho expression in the choroid plexus 
(Sathyanesan et al., 2012). The levels of CSF α-Klotho were not measured in this study, but if 
we assume CSF α-Klotho is produced by the choroid plexus, it is likely that CSF α-Klotho is 
also reduced. As such, it is not unreasonable to speculate that levels of α-Klotho in CSF may 
be inversely correlated with physiological stress, and that decreased CSF α-Klotho may be 
involved in raising the blood pressure of stressed individuals. This connection between 
stress and reduced α-Klotho is strengthened by the observation that women with chronic 
psychological stress caused by raising a child on the autistic spectrum have lower levels of α-
Klotho in serum than women raising a non-autistic child (Prather et al., 2015). Thus, it is 
quite plausible that stress decreases α-Klotho expression at multiple locations, and is 
therefore central to the effects of elevated stress on aging. 
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We would suggest that the above reports make the medulla oblongata a sensible starting 
point for studies aimed at identifying the targets of CSF α-Klotho. Initial experiments testing 
this idea could take the form of ex vivo electrophysiological studies on the medulla 
oblongata, with recordings taken in the presence or absence of recombinant α-Klotho. 
Parallel investigations could in principle be performed comparing explants from α-Klotho 
deficient and wild-type animals, although these would require prior establishment of 
whether α-Klotho is expressed in the medulla oblongata or not. 
To confirm these data at the whole animal level, CSF α-Klotho can be knocked down by 
intracerebroventricular injection of siRNA, while recombinant α-Klotho can be efficiently 
administered via the same route (Chen et al., 2015b; Wang and Sun, 2010) . However, loss-
of-function studies can perhaps be performed more cleanly with the use of choroid plexus 
specific knockout. In particular, Crouthamel and co-workers have reported the generation of 
transgenic mice with choroid plexus-specific expression of cre (Crouthamel et al., 2012). This 
animal can in principle be crossed with a floxed α-Klotho mouse. Thus, the tools exist to 
uncover further the function of CSF α-Klotho. 
2.2.8 What explains the opposing phenotypes of KL-VS carriers and homozygotes on 
cognition?  
The association between the KL-VS allele and altered higher brain function clearly 
demonstrate that α-Klotho function is conserved in humans. Nonetheless the apparent 
contradiction between data for heterozygous and homozygous individuals makes this 
evidence hard to interpret and leads to a mechanistic conundrum: how can one copy of KL-
VS be good, but two copies bad?  
We would suggest that the answer is in fact quite straightforward. KL-VS might enhance one 
function of α-Klotho while simultaneously compromising another such that when one KL-VS 
allele is present the benefits of the gained function outweigh the deficits of the partially lost 
function. However, when two copies are present the loss of function becomes too great to 
be overcome.  
Intriguingly, certain data support this idea. KL-VS is reported to enhance secretion of s-KL 
(Arking et al., 2002), and in agreement, KL-VS heterozygotes display a small increase in 
serum α-Klotho (Dubal et al., 2014). KL-VS carries also appears to enhance m-KL function, by 
increasing the interaction between this protein and FGF receptors, thereby strengthening 
FGF23 signaling (Tucker Zhou et al., 2013). At the same time, KL-VS is reported to reduce 
glucosidase activity (Arking et al., 2002). Taking these observations together, a prediction 
can be made. In heterozygotes, KL-VS causes a decrease in glucosidase activity that can be 
tolerated; any negative effects are outweighed by improved FGF23 signaling and/or higher 
levels of s-KL. In KL-VS homozygotes however, FGF23 signaling and s-KL secretion are 
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increased further, but the loss of glucosidase activity now becomes a limitation, presumably 
to such an extent that the individual’s health is jeopardized.  
Testing these ideas in animal models will be difficult, as it will require separating the 
functions of membrane-bound from shed and soluble forms of α-Klotho, as well as 
distinguishing the effects of altered glucosidase activity from gains/losses of all function. 
However, key to this is the requirement for α-Klotho glucosidase activity. At present we 
have no evidence that this enzymatic activity is required for cognition.  
Thus as a first step, we would contend that the need for α-Klotho glucosidase activity in vivo 
should be determined. Traditionally, the requirement for an enzymatic activity – as opposed 
to the requirement for the expression of an enzyme – can be demonstrated in one of two 
ways: by pharmacological inhibition, or with the use of a catalytically inactive mutant. To 
the best of our knowledge there are no specific α-Klotho inhibitors available, although the 
modified sugar D-Saccharic acid 1,4-lactone monohydrate has been used in vitro 
(e.g.(Sopjani et al., 2011)). Thus direct inhibition in vivo is currently not possible. By contrast, 
a knock-in mouse lacking glucosidase may be possible, as the key glutamic acid residues 
within the two catalytic sites have been identified (Tohyama et al., 2004). Mutating these 
residues for unrelated amino acids can be expected to ablate the glucosidase activity of α-
Klotho. Before these mutations can be introduced into a transgenic animal one would first 
need to confirm in vitro that catalytic activity is lost but that the other functions of α-Klotho 
are retained. However, in principle at least, a genetic approach like this can verify the 
requirement for glucosidase activity in vivo, which will take us closer to resolving the 
mystery behind cognition and longevity in the KL-VS variant. 
4. CONCLUSIONs 
We believe the above data make a clear case for a central role for α-Klotho in controlling 
cognition in many mammal species, including man. In healthy animals α-Klotho appears to 
fulfil a homeostatic purpose, necessary for the normal survival and function of neurons and 
other brain cells, although the precise nature of that role remains to be elucidated. With 
age, and in response to various insults to the health of the organism, α-Klotho expression 
falls, leading to reductions in higher brain function that typically occur with aging. It is likely 
that these events parallel age-related changes to the functions of other bodily organs 
following decreases in α-Klotho.  
However, a number of key experimental questions need addressing before the role of α-
Klotho in cognition can be fully understood. We hope to have contributed towards defining 
these challenges. Nonetheless, beyond the role of brain α-Klotho, fundamental gaps in our 
knowledge about the basic biology of this protein remain. As mentioned, the roles of the 
different types of α-Klotho need to be further elucidated. Moreover, there is some evidence 
to suggest α-Klotho may behave differently in males and females, since levels are higher in 
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the CSF of men than women (Semba et al., 2014), and α-Klotho gene expression can be 
induced by testosterone (Hsu et al., 2014). The potential implications of these observations 
are intriguing and further work is clearly needed. But in any case, in light of the connections 
between decreased α-Klotho expression and a growing list of age related conditions, it is 
clear that the study of this protein will be hugely beneficial for understanding human aging, 
in the brain and beyond. 
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LEGENDS 
Figure 1. Different forms of α- Klotho protein. Two different transcripts can be generated 
from klotho gene. mRNA 1 is translated to the membrane form of α- Klotho (m-KL), which 
can be shed by ADAM 10 or ADAM 17 and produce a number of soluble forms. Another 
soluble form is obtained from the mRNA 2 (an alternative splicing variant), this protein has 
an additional C-terminal sequence, and is secreted to the extracellular medium.   
 
Figure 2. α-Klotho and CNS function: Lessons from klotho-/- mice. Here we summarize the 
main findings from studies of kl/kl mice which are directly related to impaired synaptic 
function, cholinergic signaling, oxidative and apoptotic stress. All of these features are well 
known to be related to impaired cognitive function. Depicted in purple are therapeutic 
interventions that have been reported to be capable of reverting these alterations and 
improving cognition in kl/kl mice. 
 
Figure 3. Effects of increased α-Klotho in neural cell signaling pathways. A number of cell 
signaling pathways have been reported to be modulated by α-Klotho. The data point to 
important roles in neuroprotection and myelination. 
 
Figure 4. The modulation of different α-Klotho pools following potentially harmful or 
protective stimuli. A number of studies have reported factors that can up or downregulate 
α-Klotho levels, reinforcing its relevance as a neuroprotectant and as a therapeutic target 
for many diseases. But an important question remaining is if and how the different α-Klotho 
pools interact.  
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Figure 1. Different forms of α- Klotho protein. Two different transcripts can be generated from
klotho gene. mRNA 1 is translated to the membrane form of α- Klotho (m-KL), which can be shed by
ADAM 10 or ADAM 17 and produce a number of soluble forms. Another soluble form is obtained from
the mRNA 2 (an alternative splicing variant), this protein has an additional C-terminal sequence, and is
secreted to the extracellular medium.
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Figure 2. α-Klotho and CNS function: Lessons from klotho-/- mice. Here we summarize the
main findings from studies of kl/kl mice which are directly related to impaired synaptic function,
cholinergic signaling, oxidative and apoptotic stress. All of these features are well known to be
related to impaired cognitive function. Depicted in purple are therapeutic interventions that have
been reported to be capable of reverting these alterations and improving cognition in kl/kl mice.
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Figure 3. Effects of increased α-Klotho in neural cell signaling pathways. A number of cell
signaling pathways have been reported to be modulated by α-Klotho. The data point to important
roles in neuroprotection and myelination.
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number of studies have reported factors that can up or downregulate α-Klotho levels, reinforcing its relevance as a
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